Skip to main content

KIR2DL5/CD158f Antibody (UP-R1)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-62222

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry, Immunocytochemistry

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # UP-R1

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Human CD158f-Ig fusion protein

Specificity

The antibody MEM-59 recognizes neuraminidase-sensitive epitope on CD43 (Leukosialin), a 95-135 kDa type I transmembrane glycoprotein (mucin-type) which is involved in lymphocyte activation. CD43 is expressed by platelets and at high levels on the surface of all leukocytes; it is negative on resting B lymphocytes and erythrocytes.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Theoretical MW

60 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for KIR2DL5/CD158f Antibody (UP-R1)

Flow (Cell Surface): KIR2DL5/CD158f Antibody (UP-R1) [NBP2-62222]

Flow (Cell Surface): KIR2DL5/CD158f Antibody (UP-R1) [NBP2-62222]

Flow (Cell Surface): KIR2DL5/CD158f Antibody (UP-R1) [NBP2-62222] - Surface staining of human peripheral blood with anti-CD158f (UP-R1) purified / GAM-APC.
Flow (Cell Surface): KIR2DL5/CD158f Antibody (UP-R1) [NBP2-62222]

Flow (Cell Surface): KIR2DL5/CD158f Antibody (UP-R1) [NBP2-62222]

Flow (Cell Surface): KIR2DL5/CD158f Antibody (UP-R1) [NBP2-62222] - Surface staining of human peripheral blood with anti-CD158f (UP-R1) PE.

Applications for KIR2DL5/CD158f Antibody (UP-R1)

Application
Recommended Usage

Flow Cytometry

1-4 ug/ml

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS (pH 7.4)

Preservative

0.9% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: KIR2DL5/CD158f

Killer cell immunoglobulin-like receptors (KIRs) are transmembrane glycoproteins expressed by natural killer cells andsubsets of T cells. The KIR genes are polymorphic and highly homologous and they are found in a cluster on chromosome19q13.4 within the 1 Mb leukocyte receptor complex (LRC). The gene content of the KIR gene cluster varies amonghaplotypes, although several "framework" genes are found in all haplotypes (KIR3DL3, KIR3DP1, KIR3DL4,KIR3DL2). The KIR proteins are classified by the number of extracellular immunoglobulin domains (2D or 3D) and bywhether they have a long (L) or short (S) cytoplasmic domain. KIR proteins with the long cytoplasmic domain transduceinhibitory signals upon ligand binding via an immune tyrosine-based inhibitory motif (ITIM), while KIR proteins withthe short cytoplasmic domain lack the ITIM motif and instead associate with the TYRO protein tyrosine kinase bindingprotein to transduce activating signals. The ligands for several KIR proteins are subsets of HLA class I molecules;thus, KIR proteins are thought to play an important role in regulation of the immune response. (provided by RefSeq)

Long Name

Killer Cell Immunoglobulin-like Receptor, Two Domain Long Cytoplasmic Tail, 5

Alternate Names

CD158f, KIR2DL5A

Gene Symbol

KIR2DL5A

Additional KIR2DL5/CD158f Products

Product Documents for KIR2DL5/CD158f Antibody (UP-R1)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for KIR2DL5/CD158f Antibody (UP-R1)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...